Brain Cancer Clinical Trials

24 trials recruiting in Canada.

Cancer

Recruiting Drug Device Behavioral Older adults Healthy volunteers

14 trials

Comparing Etoposide with Tamoxifen for glioblastoma multiforme

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives Etoposide. Group B receives Tamoxifen.

One site, in Edmonton

Phase 2
2 groups
One site, in Edmonton
Recruiting

Official title: Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

Glioblastoma Multiforme · AHS Cancer Control Alberta

Testing Belzutifan for pheochromocytoma/paraganglioma

Explore this study →

Everyone in this study is in one group and receives Belzutifan.

Sites in Calgary and Toronto

Phase 2
1 group
Sites in Calgary and Toronto
Recruiting

Official title: Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Pheochromocytoma/Paraganglioma · Merck Sharp & Dohme LLC

Comparing Blood Brain Barrier Opening with Pembrolizumab for brain tumor

Explore this study →

There are 2 groups in this study. Group A receives one or more of: Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab, Cemiplimab, Nivolumab and Iptilimumab. Group B, the comparison group, receives one or more of: Pembrolizumab, Atezolizumab, Cemiplimab, Nivolumab and Iptilimumab.

One site, in Toronto

Phase 3
2 groups
One site, in Toronto
Recruiting

Official title: Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Brain Tumor · InSightec

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for brain cancer.

Comparing Chemo-Radiotherapy with concurrent with Temozolomide monotherapy for glioblastoma multiforme

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives Chemo-Radiotherapy with concurrent temozolomide.. Group B receives Temozolomide monotherapy.

Sites in Calgary and Edmonton

Phase 2
2 groups
Sites in Calgary and Edmonton
Recruiting

Official title: Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients

Glioblastoma Multiforme · AHS Cancer Control Alberta

Comparing IA Carboplatin + IA Caelyx with IA Carboplatin + IA Etoposide Phosphate for glioblastoma multiforme

Explore this study →

There are 2 groups in this study. Group A receives IA Carboplatin + IA Caelyx. Group B receives IA Carboplatin + IA Etoposide Phosphate.

One site, in Sherbrooke

Phase 2
2 groups
One site, in Sherbrooke
Recruiting

Official title: Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma

Glioblastoma Multiforme · Université de Sherbrooke

Testing TRANEXAMIC ACID against a placebo for brain tumor

Explore this study →

There are 2 groups in this study. Group A receives TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION. Group B, the placebo group, receives Placebo.

One site, in Halifax

Phase 3
2 groups
One site, in Halifax
Recruiting

Official title: The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies

Brain Tumor · Stephen Lownie

Testing Saturation Transfer (ST)-MRI for low-grade glioma

Explore this study →

Everyone in this study is in one group and receives Saturation Transfer (ST)-MRI.

2 sites in Toronto

1 group
2 sites in Toronto
Recruiting

Official title: CEST in Low-grade Glioma Study

Low-grade Glioma · Sunnybrook Health Sciences Centre

Testing Afatinib with Dasatinib for glioblastoma

Explore this study →

Everyone in this study is in one group, which receives one or more of: Afatinib, Dasatinib, Palbociclib, Everolimus and Olaparib.

One site, in Calgary

Early Phase 1
1 group
One site, in Calgary
Recruiting

Official title: Pilot Trial for Treatment of Recurrent Glioblastoma

Glioblastoma · AHS Cancer Control Alberta

Testing Optune® device with Temozolomide against a placebo for glioblastoma

Explore this study →

There are 2 groups in this study. Group A receives one or more of: Optune® device, Temozolomide and Pembrolizumab. Group B, the placebo group, receives one or more of: Optune® device, Temozolomide and Placebo.

Sites in Montreal, Edmonton and 4 more cities

Phase 3
2 groups
Sites in Edmonton, Hamilton and 4 more cities
Recruiting

Official title: EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Glioblastoma · NovoCure GmbH

Testing Daily TMZ for glioblastoma

Explore this study →

Everyone in this study is in one group and receives Daily TMZ.

One site, in Toronto

Phase 2
1 group
One site, in Toronto
Recruiting

Official title: Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma

Glioblastoma · Sunnybrook Health Sciences Centre

Comparing Morning administration of TMZ with Evening administration of TMZ for IDH-wildtype glioblastoma

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives Morning administration of TMZ. Group B, the comparison group, receives Evening administration of TMZ.

Sites in London and Ottawa

2 groups
Sites in London and Ottawa
Recruiting

Official title: The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma

IDH-Wildtype Glioblastoma · Ottawa Hospital Research Institute

Comparing 6 approaches for glioblastoma multiforme

Explore this study →

There are 6 groups in this study. Groups A, B, C, D, E and F receive IA Carbo+ Radiation.

One site, in Sherbrooke

Phase 1
6 groups
One site, in Sherbrooke
Recruiting

Official title: IA Carboplatin + Radiotherapy in Relapsing GBM

Glioblastoma Multiforme · Université de Sherbrooke

Comparing 17 approaches for glioblastoma

Explore this study →

There are 17 groups in this study. Group A, the comparison group, receives one or more of: Temozolomide, Lomustine and Radiation. Group B receives Regorafenib. Group C receives Paxalisib. …and 6 more groups.

Sites in Toronto, Montreal and 1 more city

Phase 2
17 groups
Sites in Toronto, Montreal and 1 more city
Recruiting

Official title: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma · Global Coalition for Adaptive Research

Testing Dose painting + Reduced Margins for glioblastoma (GBM)

Explore this study →

Everyone in this study is in one group and receives Dose painting + Reduced Margins.

One site, in Toronto

1 group
One site, in Toronto
Recruiting

Official title: UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4

Glioblastoma (GBM) · Sunnybrook Health Sciences Centre

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Brain Cancer trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.